SCHEMBL7090589

SCHEMBL7090589

CSc1ccc(C(=O)C(=O)c2ccc(C)c(C)c2)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 3/20 0.65
CES1 P23141 3/20 0.65
HPGD P15428 2/20 0.55
BLM P54132 2/20 0.55
POLB P06746 2/20 0.55
CTDSP1 Q9GZU7 1/20 0.55
MAPT P10636 2/20 0.48
TDP1 Q9NUW8 1/20 0.48
PLK1 P53350 1/20 0.47
HTT P42858 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
CYP1A2 P05177 2/20 0.42
CYP3A4 P08684 2/20 0.42
CYP2C9 P11712 2/20 0.42
NPC1 O15118 2/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C19 P33261 1/20 0.42
RAB9A P51151 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5859663 0.84 PLK1 (0.61) CES2CES1HPGDBLMMAPT
SCHEMBL9420251 0.84 CES2 (0.79) CES2CES1HPGDPOLBMAPT
SCHEMBL7089334 0.80 CES2 (0.70) CES2CES1HPGDBLMMAPT
SCHEMBL7090904 0.79 PARP1 (0.50) CES2CES1HPGDPOLBCTDSP1
SCHEMBL2156354 0.79 CES2 (1.00) CES2CES1POLBMAPTTDP1
SCHEMBL7088209 0.77 POLB (0.48) CES2CES1HPGDBLMPOLB
Ammonia Solution, Strong SCHEMBL28154338 0.77 CES2 (0.96) CES2CES1POLBMAPTTDP1
SCHEMBL7088584 0.76 TSHR (0.50) CES2CES1HPGDMAPTPLK1
SCHEMBL7084463 0.76 CES2 (0.68) CES2CES1MAPTPLK1SMN1; SMN2
SCHEMBL7090547 0.76 CES2 (0.65) CES2CES1HPGDMAPTPLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030050330-A1 4,5-subtstituted imdazolyl compounds for the treatment of inflammation G.D. SEARLE & CO. 2003-03-13 US disclosed
EP-0772601-B1 4,5-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION SEARLE & CO (US) 2002-09-18 EP disclosed
US-6426360-B1 ANTIARTHRITIC AGENTS G D SEARLE & CO. 2002-07-30 US disclosed
EP-1211244-A2 4,5-substitued imidazolyl compounds for the treatment of inflammation G.D. Searle & Co. (US) 2002-06-05 EP disclosed
EP-0772601-A1 4,5-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1997-05-14 EP disclosed
WO-1996003387-A1 4,5-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1996-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030050330-A1 4,5-subtstituted imdazolyl compounds for the treatment of inflammation AHR, HACL2, IRAK2 CES2 984/4885CES1 374/4885HPGD 1005/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.